

IND SAFETY REPORT: INITIAL WRITTEN REPORT

TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA

FAX: 301-796-9845

1. IND NUMBER

**69896
74019**

2. AGENT NAME

**BAY 43-9006 tosylate (BAY 54-9085; sorafenib tosylate)
Sunitinib malate (SU011248 L-malate; Sutent®)**

3. DATE

March 31, 2009

4. SPONSOR

Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER'S NAME, TITLE, AND INSTITUTION

**John Wright, MD, PhD-Associate Branch Chief for Investigational Therapeutics 2,
Investigational Drug Branch, CTEP, DCTD, NCI**

6. PHONE NUMBER

301-496-1196

**S. Percy Ivy, MD - Associate Branch Chief for Investigational Therapeutics 1,
Investigational Drug Branch, CTEP, DCTD, NCI**

7. FAX NUMBER

301-402-0428

8. PROTOCOL NUMBER (AE #)

E2805 (1704399)

9. PATIENT IDENTIFICATION

28961

10. AGE

63

11. SEX

Female

12. DESCRIPTION OF ADVERSE EVENT

The patient is a 63-year-old female with renal cell carcinoma who experienced a grade 4 proteinuria and grade 4 decreased hemoglobin while on phase 3 trial comparing adjuvant sorafenib tosylate or placebo and sunitinib malate or placebo. The patient began the investigational therapy on September 4, 2008, and received the last doses of sorafenib tosylate or placebo on February 11, 2009 (Cycle 4, Day 43) and sunitinib malate or placebo on January 28, 2009. During the time that she was taking the medications, she did have side effects of diarrhea, nausea, vomiting, and easy bruising. On February 11, 2009, the patient had labs drawn prior to starting Cycle 5, as per the protocol. Laboratory findings showed a hemoglobin of 6.1 g/dL (reference range of 12.1-15.3 g/dL), total protein 344 mg/dL (reference range of 60-80 mg/dL). She had a history of proteinuria. The patient received two units packed red blood cells to correct her anemia. All her medications were held. She will continue to have weekly monitoring until each event will be returned to grade 1. Additional information has been requested from the investigative site. There is a reasonable possibility that the experience is related to the investigational therapy.

13. DOSE, ROUTE, AND SCHEDULE (Cycle = 42 days)

**Sorafenib or Placebo 400 mg PO twice a day x 6 weeks for 9 cycles, or
Sunitinib malate or Placebo 50 mg PO daily x 4 weeks followed by rest for 2 weeks for 9 cycles**

14. DATES OF TREATMENT

The patient started the investigational drug therapy on September 4, 2008, and received the last doses of sorafenib or placebo on February 11, 2009 (Cycle 4, Day 43) and the last dose of sunitinib malate or placebo on January 28, 2009.

15. ACCRUAL AND IND EXPERIENCE

**Number of patients enrolled in NCI-sponsored clinical trials using BAY 43-9006 tosylate = 4884, and using sunitinib malate = 1633.
There have been 107 other cases of decreased hemoglobin and 14 other cases of proteinuria reported to the NCI though AdEERS as serious adverse events for BAY 43-9006, and 19 other cases of decreased hemoglobin and 4 other cases of proteinuria reported to the NCI though AdEERS as serious adverse events for sunitinib malate.**

AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOWUP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR312.32(d)(2).

DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/ SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.

0002